Access
Tirzepatide Availability and Supply
Tirzepatide availability has fluctuated since launch, and shortage status has had direct consequences for compounded supply, because drug-shortage designations affect what compounding is permissible. Supply conditions and shortage designations change, sometimes quickly, so current status should be checked against FDA sources rather than any secondary summary — including this one. Local pharmacy availability can also differ from national supply status.
Key takeaways
- Availability has fluctuated since launch, affecting both brand access and compounded supply.
- Drug-shortage status directly affects what compounding is permissible.
- Changes to shortage designations have had immediate commercial consequences in this market.
- Current status should be checked against FDA sources, not provider marketing.
- Local pharmacy availability can differ from national supply status.
| Historical pattern | Fluctuating availability since launch |
|---|---|
| Link to compounding | Shortage status affects permissible compounding |
| Volatility | Designations have changed repeatedly |
| Authoritative source | FDA drug shortage information |
| Local variation | Pharmacy-level availability can differ from national status |
Why does shortage status matter so much to compounded supply?
Because the regulatory rationale for compounding a copy of an approved drug is substantially weakened when the approved drug is actually available. Shortage designations have therefore been closely linked to the legitimacy of large-scale compounded supply, and changes to those designations have reshaped the market quickly.
For a consumer, this means the compounded option's availability is less stable than its marketing suggests.
What should you do if supply is disrupted?
Talk to the prescriber rather than switching sources independently. Interruption has consequences — returning after a long gap can reintroduce the gastrointestinal effects that escalation had settled — and a prescriber can advise on alternatives.
Switching to an unverified source because of a supply gap is how people end up with products from sellers they would otherwise have avoided.
What the evidence shows
- That availability has fluctuated and that shortage status affects compounding permissibility.
What the evidence does not show
- Current shortage or availability status — check FDA sources.
- Availability at your specific pharmacy.
Related: Compounding regulation · Cost
What does the market actually charge?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Monthly membership fee | $79 | $178 |
| Consultation fee | $0 | $178 |
| Shipping | $0 | $178 |
| Series | Start | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| TRYM Health | 0$ | 750.0$ | 1500.0$ | 2250.0$ | 3000.0$ |
| NexLife | 0$ | 1116.0$ | 2232.0$ | 3348.0$ | 4464.0$ |
| Fridays | 0$ | 1440.0$ | 2880.0$ | 4320.0$ | 5760.0$ |
| Product | Regulatory status | What that means for availability |
|---|---|---|
| Zepbound (tirzepatide) | FDA approved for chronic weight management | Available by prescription through normal pharmacy channels |
| Mounjaro (tirzepatide) | FDA approved for type 2 diabetes | Available by prescription through normal pharmacy channels |
| Compounded tirzepatide injection | Not FDA approved; shortage resolved, enforcement discretion ended | Routine compounding no longer permitted as an essentially-a-copy product |
| Compounded oral, sublingual, ODT or troche tirzepatide | Not FDA approved in any form | Never covered by shortage-era compounding; no approved oral tirzepatide product exists |
| Research-grade or grey-market tirzepatide | Not a medicine; outside the regulated supply chain | No pharmacy accountability, no verified identity, purity, or sterility |
Why is tirzepatide pricing so hard to compare?
Four structural features of this market make direct comparison difficult, and none of them is accidental. Prices are frequently advertised as a starting figure that applies to a subset of doses or commitment lengths. Medication and service are often billed separately, so the headline covers part of the cost. Introductory rates differ from recurring rates, and the introductory figure is the one displayed. And commitment tiers convert a monthly price into a prepayment, which changes what the number means.
The combined effect is that two advertised figures can differ by a factor of two while the actual recurring costs are nearly identical, or appear nearly identical while the actual costs differ substantially. This is why every figure on this site is normalised before it is compared, and why providers whose figures cannot be normalised are excluded rather than estimated.
| Cost component | Typically advertised? | Typically included in the headline? | Effect on real cost |
|---|---|---|---|
| Medication | Yes | Sometimes | The base figure |
| Membership or programme fee | Sometimes | Rarely | Commonly $40-$80 per month |
| Initial consultation | Sometimes | Rarely | One-off, but can be substantial |
| Shipping | Sometimes | Varies | Small but recurring |
| Dose surcharge above a threshold | Rarely | Almost never | Can change which provider is cheapest |
| Laboratory work | Rarely | No | Variable, sometimes billed to insurance |
| Renewal after introductory period | Rarely displayed | No | Frequently the largest single jump |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Recurring membership fee | $79 | $178 |
| Shipping, billed monthly | $10 | $188 |
What does treatment cost over a realistic horizon?
Because SURMOUNT-4 established that stopping produces substantial regain, the planning horizon for tirzepatide is years rather than months. A monthly difference that looks trivial compounds into a material sum across that period, and an introductory discount that looks generous becomes close to irrelevant.
| Provider | Monthly | One year | Two years | Three years |
|---|---|---|---|---|
| TRYM Health | $125 | $1,500 | $3,000 | $4,500 |
| NexLife | $186 | $2,232 | $4,464 | $6,696 |
| Fridays | $240 | $2,880 | $5,760 | $8,640 |
| Mochi Health | $278 | $3,336 | $6,672 | $10,008 |
| Eden | $298 | $3,576 | $7,152 | $10,728 |
These projections assume the price and the dose are unchanged, and neither is guaranteed. Dose coverage is unverified for most providers in this dataset, and a surcharge that applies above a dose threshold would raise the later years of every column. The projection is therefore a floor rather than a forecast.
What does this page cover, and what does it deliberately leave out?
This page addresses Shortage status, supply and pharmacy availability and compounding effects, organised around the primary question of tirzepatide availability. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Shortage status | Covered on this page | Captured record |
| Supply | Covered on this page | Captured record |
| Pharmacy availability and compounding effects | Covered on this page | Captured record |
| Individualized clinical instruction | Deliberately not covered | Belongs with your insurer and the provider |
What are the limits of what this page can tell you?
Every page on this site rests on a specific captured pricing and coverage rules, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for your insurer and the provider.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide availability.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including 503A, 503B, compounded, effective monthly cost — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
Frequently asked questions
Is tirzepatide in shortage?
Status changes; check current FDA drug shortage information rather than a secondary summary.
How does shortage affect compounded tirzepatide?
Shortage status affects what compounding is permissible, so designations directly shape compounded supply.
What should I do if my pharmacy has none?
Talk to your prescriber rather than switching to an unverified source.
Where do I check availability?
FDA drug shortage information for national status, and your pharmacy for local supply.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.